|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for LANCL1 |
 Gene summary |
| Basic gene Info. | Gene symbol | LANCL1 |
| Gene name | LanC lantibiotic synthetase component C-like 1 (bacterial) | |
| Synonyms | GPR69A|p40 | |
| Cytomap | UCSC genome browser: 2q33-q35 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001136574.1, NM_001136575.1,NM_006055.2, | |
| Description | 40 kDa erythrocyte membrane proteinG protein-coupled receptor 69ALanC (bacterial lantibiotic synthetase component C)-like 1LanC (bacterial lantibiotic synthetase component)lanC-like protein 1 | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 604155 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000115365 | ||
| HPRD : 16040 | ||
| Vega : OTTHUMG00000132991 | ||
| Protein | UniProt: O43813 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_LANCL1 | |
| BioGPS: 10314 | ||
| Pathway | NCI Pathway Interaction Database: LANCL1 | |
| KEGG: LANCL1 | ||
| REACTOME: LANCL1 | ||
| Pathway Commons: LANCL1 | ||
| Context | iHOP: LANCL1 | |
| ligand binding site mutation search in PubMed: LANCL1 | ||
| UCL Cancer Institute: LANCL1 | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0007186 | G-protein coupled receptor signaling pathway | 10944443 |
| Top |
| Ligand binding site mutations for LANCL1 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | H277 | A279T | STAD | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for LANCL1 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | H277 | A279T | -1.5472569 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for LANCL1 from PDB |
| Top |
| Differential gene expression and gene-gene network for LANCL1 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for LANCL1 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for LANCL1 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of LANCL1 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | GSH | GLUTATHIONATE(1-) | 3e73 | A | H277 | GSH | GLUTATHIONATE(1-) | 3e73 | B | H277 |
| Top |
| Conservation information for LBS of LANCL1 |
| Multiple alignments for O43813 in multiple species |
| LBS | AA sequence | # species | Species | C276 | LLVHWCHGAPG | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | C276 | LLVHWCHGSPG | 1 | Danio rerio | C322 | KGYGLCHGAAG | 3 | Danio rerio, Mus musculus, Rattus norvegicus | C322 | KGYGLCHGSAG | 1 | Homo sapiens | D367 | GCRTPDTPFSL | 3 | Homo sapiens, Danio rerio, Rattus norvegicus | D367 | GCRTADTPFSL | 1 | Mus musculus | E374 | PFSLFEGMAGT | 4 | Homo sapiens, Danio rerio, Mus musculus, Rattus norvegicus | H274 | RDLLVHWCHGA | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | H274 | RDLLVHWCHGS | 1 | Danio rerio | H277 | LVHWCHGAPGV | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | H277 | LVHWCHGSPGV | 1 | Danio rerio | H323 | GYGLCHGAAGN | 3 | Danio rerio, Mus musculus, Rattus norvegicus | H323 | GYGLCHGSAGN | 1 | Homo sapiens | K317 | YGLLKKGYGLC | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | K317 | RGLLKKGYGLC | 1 | Danio rerio | L272 | DTRDLLVHWCH | 2 | Mus musculus, Rattus norvegicus | L272 | DNRDLLVHWCH | 1 | Homo sapiens | L272 | DARDLLVHWCH | 1 | Danio rerio | P366 | HGCRTPDTPFS | 3 | Homo sapiens, Danio rerio, Rattus norvegicus | P366 | HGCRTADTPFS | 1 | Mus musculus | R364 | GEHGCRTPDTP | 2 | Homo sapiens, Rattus norvegicus | R364 | GRHGCRTPDTP | 1 | Danio rerio | R364 | GEHGCRTADTP | 1 | Mus musculus | R4 | 4 | Homo sapiens, Danio rerio, Mus musculus, Rattus norvegicus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |